REVIVAL注册研究:门诊晚期收缩性心衰患者VAD评估的基本原理、设计、基线特征与纳入标准性能
纳入标准仅使用常规临床信息,要求满足10项高危标准中至少1项。373例可评估患者1年无事件率为75.9%,非住院纳入标准识别了89%的事件患者。
要点
- REVIVAL成功招募了年主要复合终点风险约25%的门诊慢性收缩性心衰队列。
- 非住院纳入标准识别了89%的发生事件患者。
- 该注册研究信息有助于规划早期VAD使用及其他干预措施的临床试验。
核心结论
- 使用常规临床信息入组,REVIVAL成功招募了年主要复合终点风险约25%的门诊慢性收缩性心衰队列。
研究设计与样本
- 纳入标准仅使用常规临床诊疗中收集的信息,要求满足10项高危标准中至少1项;排除标准识别VAD禁忌症患者。
- 评估了高危标准的检验性能特征,主要复合终点为死亡、紧急移植或持久机械循环支持。
主要发现
- 373例在1年访视时可评估主要复合终点的患者中,无主要复合终点生存率为75.9%。
- 非住院纳入标准识别了89%的发生事件患者。
- 基线数据表明该队列病情严重程度低于MedaMACS和ROADMAP研究。
关键数值与推荐
- 纳入要求至少满足10项高危标准中的1项,这些标准源自已建立的住院和非住院死亡风险升高标志物。
临床怎么用
- REVIVAL注册研究的信息将有助于规划未来早期VAD使用及其他干预措施的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Improved understanding of the clinical course of ambulatory advanced chronic systolic heart failure may improve the provision of appropriate care and is central to the design of clinical trials in this population. METHODS: Twenty-one implanting ventricular assist device (VAD) centers enrolled 400 subjects in the Registry Evaluation of Vital Information for VADs in Ambulatory Life (REVIVAL), a prospective, observational study in ambulatory, chronic, advanced systolic heart failure, designed to identify a cohort with an approximately 25% 1-year risk of the primary composite outcome of death, urgent transplant, or durable mechanical circulatory support. Inclusion criteria utilized only information collected during routine clinical care. Exclusion criteria identified patients with contraindications to VAD. Study inclusion required at least 1 of 10 high-risk criteria derived from established hospitalization and non-hospitalization markers of increased mortality risk. We evaluated the test performance characteristics of the high-risk criteria. RESULTS: Data on 373 subjects evaluable for the primary composite outcome at the 1-year visit are presented. Baseline data were consistent with a less advanced cohort than Medical Arm for Mechanically Assisted Circulatory Support or Risk Assessment (MedaMACS) and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients (ROADMAP). Freedom from the primary composite outcome was 75.9%. Non-hospitalization inclusion criteria identified 89% of patients with events. CONCLUSIONS: Using routinely obtained clinical information for enrollment, REVIVAL successfully recruited an ambulatory chronic systolic heart failure cohort with an approximately 25% annual risk of the primary composite outcome. Information from this registry will be relevant to the planning of future trials of earlier VAD use and of other interventions in this population.
引用
- Aaronson KD, Stewart GC, Pagani FD, et al. Registry Evaluation of Vital Information for VADs in Ambulatory Life (REVIVAL): Rationale, design, baseline characteristics, and inclusion criteria performance. J Heart Lung Transplant. 2019. PMID: 31679943. doi:10.1016/j.healun.2019.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。